Clinical isolates of Coxsackie B viruses differ from laboratory strains in their receptor specificity, indicating that receptor usage can vary within a serotype and alter during infection.
Answers are grounded in this paper and cite their sources.
Supports caution against generalizing receptor use from lab strains; leaves open how isolate variation affects human Coxsackie B pathogenesis.
Coxsackie B viruses interact with two putative cell surface receptor molecules. Experiments with prototype laboratory strains suggest that all 6 coxsackie B serotypes interact with a 46-kDa protein recognized by the monoclonal antibody RmcB, whereas CB1, CB3, and CB5 may also bind to decay accelerating factor. Antireceptor monoclonal antibodies were used to study interactions between low-passage clinical coxsackie B virus isolates and the two receptors. In contrast to observations made with single prototype strains, these data indicate that receptor use by clinical isolates is not strictly related to serotype and that even prototype strains with different passage histories may differ in receptor use. Within a given serotype, variation exists in the capacity of individual virus isolates to bind to specific receptors, and variants with altered receptor specificity may arise during infection in humans and in tissue culture.
No takes yet. Share an insight, caveat, or question.
Bergelson et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: